Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Apr 13, 2010


OncoMethylome Sciences' board of directors has named Jan Groen to serve as the company's chief executive officer.

Groen was previously the president and chief operating officer of Agendia, responsible for the firm's US and European operations. He was also vice president of research and development of Quest subsidiary Focus Diagnostics, and has held numerous management and scientific positions at ViroClinics, the Erasmus Medical Center, and Akzo-Nobel.

Stratos Genomics has added Heiner Dreismann to its board of directors. Dreismann, who will be Stratos’ seventh director, was formerly CEO at Roche Molecular Diagnostics, where he also was business unit manager for PCR and microbiology.

Biochip developer Silicon Kinetics said that Eric Topol and Rick Brown have joined its board of directors.

Topol is director of the Scripps Translational Science Institute and chief academic officer at Scripps Health, and he formerly was provost and CAO at the Cleveland Clinic and founder of the Cleveland Clinic Lerner College of Medicine.

Brown previously was CEO of MicroCal and vice president of business development in Isis Pharmaceuticals' genomics division.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.